BIOVECTRA signs service agreement with Acuitas Therapeutics for unique lipid nanoparticle (LNP) delivery system used in manufacturing mRNA-based therapies Post author: Post published:October 6, 2023 Post category:uncategorized BIOVECTRA and Acuitas Therapeutics, Inc. today announced that they have entered into a technology transfer service. You Might Also Like Pioneering study finds predictive biomarker in lung adenocarcinoma November 13, 2023 Philanthropic funding boost for UK Biobank October 30, 2023 Renewed classification of primary iron overload syndromes based on Hep25/FP system April 29, 2024